

The Board of Pharmacy has received notice of the following product recall. The Board strongly encourages pharmacies to immediately review their quality assurance and recall policies and procedures to determine if any corrective action is required.

Description	Lot # / Exp Date	NDC	UPC	
NP THYROID ORAL TB30MGACEL100@	M329M18-2 11/30/20; M329J18-3 08/31/20; M329J18-2 08/31/20; M329J18-1 08/31/20; M329H18-1 07/31/20; M329A19-1 12/31/20	42192032901	34219232901	
NP THYROID ORAL TB90MGACEL100@	M331M18-2 11/30/20; M331M18-1 11/30/20; M331J18-2 08/31/20; M331J18-1 08/31/20; M331G18-1 06/30/20	42192033101	34219233101	
NP THYROID ORL TB 60MGACEL100@	M330J18-3 08/31/2020; M330J18-2A 08/31/2020	42192033001	34219233001	

Acella is recalling the above items/lots due to Acella testing finding these lots to be super-potent, having up to 115% of the labeled amount of Liothyronine. This recall is to the consumer level. Affected product started shipping September 6, 2018.